{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:33:03Z","timestamp":1793277183475,"version":"4.5.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012007","name":"Rockefeller University","doi-asserted-by":"publisher","award":["UL1TR001866"],"award-info":[{"award-number":["UL1TR001866"]}],"id":[{"id":"10.13039\/100012007","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jaci.2021.01.013","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T18:21:14Z","timestamp":1611858074000},"page":"1174-1190.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":338,"title":["Biomarkers in atopic dermatitis\u2014a review on behalf of the International Eczema Council"],"prefix":"10.1016","volume":"147","author":[{"given":"Yael","family":"Renert-Yuval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DirkJan","family":"Hijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.01.013_bib1","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1111\/all.14194","article-title":"Unraveling the complexity of atopic dermatitis: the CK-CARE approach towards precision medicine","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.01.013_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.det.2018.12.007","article-title":"What\u2019s new in atopic dermatitis","volume":"37","author":"Renert-Yuval","year":"2019","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2021.01.013_bib3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jaci.2017.04.015","article-title":"Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials","volume":"140","author":"Han","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines, 1: introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2021.01.013_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/exd.13077","article-title":"A novel molecular disease classifier for psoriasis and eczema","volume":"25","author":"Garzorz-Stark","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jaci.2020.05.048","article-title":"Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis","volume":"147","author":"He","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008946","article-title":"Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema","volume":"6","author":"Quaranta","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2021.01.013_bib11","first-page":"1712","article-title":"Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity","volume":"6","author":"Vekaria","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.jaci.2021.01.013_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1442-200X.2009.02908.x","article-title":"Changes in serum lactate dehydrogenase activity in children with atopic dermatitis","volume":"52","author":"Morishima","year":"2010","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jaci.2021.01.013_bib13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00403-011-1198-9","article-title":"Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis","volume":"304","author":"Kou","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2021.01.013_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/138027","article-title":"Stress evaluation in adult patients with atopic dermatitis using salivary cortisol","volume":"2013","author":"Mizawa","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jaci.2021.01.013_bib15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/ACI.0000000000000198","article-title":"Biomarkers for atopic dermatitis: a systematic review and meta-analysis","volume":"15","author":"Thijs","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000247419","article-title":"Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis","volume":"185","author":"Kagi","year":"1992","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2021.01.013_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/all.14080","article-title":"Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry","volume":"75","author":"Ariens","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.01.013_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjd.12943","article-title":"Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis","volume":"171","author":"Kou","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2133.1992.tb00677.x","article-title":"Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis","volume":"126","author":"Czech","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib21","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/j.1398-9995.2010.02361.x","article-title":"Stratum corneum TARC level is a new indicator of lesional skin inflammation in atopic dermatitis","volume":"65","author":"Morita","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.01.013_bib22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/intimm\/dxf044","article-title":"IFN-gamma-inducible expression of thymus and activation-regulated chemokine\/CCL17 and macrophage-derived chemokine\/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis","volume":"14","author":"Horikawa","year":"2002","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib23","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/bjd.17088","article-title":"Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell-related immunity and angiogenesis","volume":"180","author":"McAleer","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1067\/mai.2002.126079","article-title":"Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis","volume":"110","author":"Fujisawa","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib25","doi-asserted-by":"crossref","unstructured":"He H, Del Duca E, Diaz A, Kim HJ, Gay-Mimbrera J, Zhang N, et\u00a0al. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities [published online ahead of print October 1, 2020]. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2020.08.041.","DOI":"10.1016\/j.jaci.2020.08.041"},{"key":"10.1016\/j.jaci.2021.01.013_bib26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1034\/j.1399-3038.2003.00052.x","article-title":"Serum concentration of macrophage-derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children","volume":"14","author":"Leung","year":"2003","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaci.2003.12.007","article-title":"Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis","volume":"113","author":"Hijnen","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1398-9995.2005.00774.x","article-title":"Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and\u00a0eotaxin as markers of severity of atopic dermatitis","volume":"60","author":"Jahnz-Rozyk","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.01.013_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2222.2006.02430.x","article-title":"Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis","volume":"36","author":"Song","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2021.01.013_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1399-3038.2007.00692.x","article-title":"Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis","volume":"19","author":"Nakazato","year":"2008","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib31","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1399-3038.2009.00851.x","article-title":"Serum measurement of thymus and activation-regulated chemokine\/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis","volume":"20","author":"Fujisawa","year":"2009","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1525-1470.2010.01285.x","article-title":"The Self-administered Eczema Area and Severity Index in children with moderate to severe atopic dermatitis: better estimation of AD body surface area than severity","volume":"27","author":"van Velsen","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1399-3038.2011.01225.x","article-title":"Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria","volume":"23","author":"Machura","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jdermsci.2012.01.011","article-title":"Correlation between serum thymus and activation-regulated chemokine levels and stratum corneum barrier function in healthy individuals and patients with mild atopic dermatitis","volume":"66","author":"Furue","year":"2012","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2021.01.013_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1346-8138.12440","article-title":"Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis","volume":"41","author":"Kataoka","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib36","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2014.07.031","article-title":"Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity","volume":"71","author":"Landheer","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib37","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/pai.12431","article-title":"Chemokine levels in serum of children with atopic dermatitis with regard to severity and sensitization status","volume":"26","author":"Ahrens","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib38","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1111\/ijd.12830","article-title":"Serum levels of thymus and activation-regulated chemokine can be used in the clinical evaluation of atopic dermatitis","volume":"54","author":"Gu","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib39","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fimmu.2018.00630","article-title":"Exploring immune development in infants with moderate to severe atopic dermatitis","volume":"9","author":"Hulshof","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib40","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1365-2249.2002.01727.x","article-title":"Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis","volume":"127","author":"Kakinuma","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2011.05.042","article-title":"Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response","volume":"128","author":"Tintle","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib42","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Suarez-Farinas","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib43","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2018.02.047","article-title":"Serum from Asian patients with atopic dermatitis is characterized by TH2\/TH22 activation, which is highly correlated with nonlesional skin measures","volume":"142","author":"Wen","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib44","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.4049\/jimmunol.174.3.1723","article-title":"CCL18 is expressed in atopic dermatitis and mediates skin homing of human memory T cells","volume":"174","author":"Gunther","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib45","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1365-2133.2006.07201.x","article-title":"Significance of interleukin-16, macrophage-derived chemokine, eosinophil cationic protein and soluble E-selectin in reflecting disease activity of atopic dermatitis--from laboratory parameters to clinical scores","volume":"154","author":"Angelova-Fischer","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jdermsci.2006.08.004","article-title":"Macrophage-derived chemokine (MDC)\/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis","volume":"44","author":"Hashimoto","year":"2006","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2021.01.013_bib47","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jaad.2019.04.036","article-title":"The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease","volume":"81","author":"Brunner","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib48","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1365-2133.1998.02273.x","article-title":"8-hydroxydeoxyguanosine in urine as an index of oxidative damage to DNA in the evaluation of atopic dermatitis","volume":"138","author":"Tsuboi","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2230.2002.00987.x","article-title":"Serum cytokine levels in atopic dermatitis","volume":"27","author":"Yoshizawa","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0923-1811(01)00174-8","article-title":"Flow cytometric analysis of IL-4, IL-13 and IFN-gamma expression in peripheral blood mononuclear cells and detection of circulating IL-13 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the disease","volume":"29","author":"Kaminishi","year":"2002","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2021.01.013_bib51","doi-asserted-by":"crossref","first-page":"73098","DOI":"10.1155\/MI\/2006\/73098","article-title":"The relationship between serum levels of total IgE, IL-18, IL-12, IFN-gamma and disease severity in children with atopic dermatitis","volume":"2006","author":"Aral","year":"2006","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaci.2021.01.013_bib52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1468-3083.2007.02399.x","article-title":"The role of selected neuropeptides in pathogenesis of atopic dermatitis","volume":"22","author":"Salomon","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2021.01.013_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/039463201102400103","article-title":"Correlations of serum interleukin-16, total IgE, eosinophil cationic protein and total eosinophil counts with disease activity in children with atopic dermatitis","volume":"24","author":"Wu","year":"2011","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jaci.2021.01.013_bib54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Suarez-Farinas","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib55","first-page":"WC01","article-title":"Immunoglobulin E, interleukin-18 and interleukin-12 in patients with atopic dermatitis: correlation with disease activity","volume":"9","author":"Zedan","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.jaci.2021.01.013_bib56","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2340\/00015555-1864","article-title":"Malassezia spp.-specific immunoglobulin E level is a marker for severity of atopic dermatitis in adults","volume":"95","author":"Glatz","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2021.01.013_bib57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5114\/ada.2016.60614","article-title":"Selected immunological parameters in clinical evaluation of patients with atopic dermatitis","volume":"33","author":"Rosinska-Wieckowicz","year":"2016","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jaci.2021.01.013_bib58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease","volume":"137","author":"Ungar","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","article-title":"Atopic dermatitis in African American patients is TH2\/TH22-skewed with TH1\/TH17 attenuation","volume":"122","author":"Sanyal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib60","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1346-8138.1990.tb01679.x","article-title":"Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis","volume":"17","author":"Mukai","year":"1990","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib61","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1398-9995.1997.tb01236.x","article-title":"Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood","volume":"52","author":"Halmerbauer","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.01.013_bib62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1399-3038.2011.01241.x","article-title":"IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis","volume":"23","author":"Raap","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2021.01.013_bib64","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22-producing \u201cT22\u201d T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib65","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","article-title":"Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin","volume":"138","author":"Esaki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib66","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1006\/cyto.1996.0184","article-title":"T cell subsets and cytokines in allergic and non-allergic children, I: analysis of IL-4, IFN-gamma and IL-13 mRNA expression and protein production","volume":"9","author":"Koning","year":"1997","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2021.01.013_bib67","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/jdv.13160","article-title":"Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin","volume":"29","author":"Szegedi","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2021.01.013_bib68","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jamadermatol.2019.2983","article-title":"Use of tape strips to detect immune and barrier abnormalities in the skin of children with early-onset atopic dermatitis","volume":"155","author":"Guttman-Yassky","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib69","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.0736-8046.2004.21600.x","article-title":"Serum concentration of IL-18 correlates with disease extent in young children with atopic dermatitis","volume":"21","author":"Hon","year":"2004","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib70","first-page":"560","article-title":"Interleukin-18 is elevated in the horny layer in patients with atopic dermatitis and is associated with Staphylococcus aureus colonization","volume":"164","author":"Inoue","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib71","first-page":"128","article-title":"Clinical significance of serum interleukin-18 concentration in the patients with atopic dermatitis [in Korean]","volume":"27","author":"Park","year":"2007","journal-title":"Korean J Lab Med"},{"key":"10.1016\/j.jaci.2021.01.013_bib72","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaad.2019.10.039","article-title":"The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature","volume":"82","author":"Pavel","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib73","first-page":"54","article-title":"Interleukin-18 correlates with interleukin-4 but not interferon-gamma production in lymphocyte cultures from atopic dermatitis patients after staphylococcal enterotoxin B stimulation","volume":"35","author":"Suwarsa","year":"2017","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib74","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1067\/mai.2003.114","article-title":"Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris","volume":"111","author":"Kakinuma","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib75","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2230.2004.01501.x","article-title":"Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in children","volume":"29","author":"Hon","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib76","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0923-1811(95)96802-T","article-title":"Elevation of serum-soluble E-selectin in atopic dermatitis","volume":"10","author":"Morita","year":"1995","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2021.01.013_bib77","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0091-6749(97)70060-5","article-title":"Soluble E-selectin as a marker of disease activity in atopic dermatitis","volume":"99","author":"Yamashita","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib78","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1034\/j.1399-3038.2003.00057.x","article-title":"Soluble E-selectin and soluble ICAM-1 levels as markers of the activity of atopic dermatitis in children","volume":"14","author":"Wolkerstorfer","year":"2003","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib79","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","article-title":"The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins","volume":"7","author":"Brunner","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2021.01.013_bib80","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.anai.2019.10.013","article-title":"Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis","volume":"124","author":"He","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib81","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/all.14490","article-title":"Tape-strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in non-lesional skin","volume":"76","author":"Pavel","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.01.013_bib82","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.15609","article-title":"Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre","volume":"33","author":"Olesen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2021.01.013_bib83","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1399-3038.2011.01174.x","article-title":"Exploring CCL18, eczema severity and atopy","volume":"22","author":"Hon","year":"2011","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib84","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib85","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-2249.2003.02273.x","article-title":"Significant elevation of serum levels of eotaxin-3\/CCL26, but not of eotaxin-2\/CCL24, in patients with atopic dermatitis: serum eotaxin-3\/CCL26 levels reflect the disease activity of atopic dermatitis","volume":"134","author":"Kagami","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib86","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaci.2019.01.015","article-title":"Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis","volume":"144","author":"Zhou","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib87","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2340\/00015555-2723","article-title":"Increased interleukin-19 expression in cutaneous T-cell lymphoma and atopic dermatitis","volume":"97","author":"Oka","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2021.01.013_bib88","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1038\/s41598-019-41609-z","article-title":"Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay","volume":"9","author":"Konrad","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2021.01.013_bib89","first-page":"41","article-title":"Scoring atopic dermatitis: the simpler the better?","volume":"69","author":"Costa","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2021.01.013_bib90","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jdermsci.2004.09.001","article-title":"Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC\/CCL17 and MDC\/CCL22 production by PBMCs from patients with atopic dermatitis","volume":"36","author":"Furukawa","year":"2004","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2021.01.013_bib91","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jaci.2014.03.003","article-title":"Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology","volume":"133","author":"Khattri","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib92","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0625.2009.00971.x","article-title":"CC chemokines as potential immunologic markers correlated with clinical improvement of atopic dermatitis patients by immunotherapy","volume":"19","author":"Kwon","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib93","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000448400","article-title":"Stratum corneum tape stripping: monitoring of inflammatory mediators in atopic dermatitis patients using topical therapy","volume":"170","author":"Koppes","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib94","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.01.013_bib95","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","article-title":"Oral Janus kinase\/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib96","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib97","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jaci.2019.06.047","article-title":"Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial","volume":"144","author":"Bissonnette","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib98","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib99","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3389\/fimmu.2020.01768","article-title":"Tape-strip proteomic profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers","volume":"11","author":"He","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib100","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jaci.2004.05.066","article-title":"Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment","volume":"114","author":"Simon","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib101","first-page":"240","article-title":"Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments","volume":"32","author":"Yasukochi","year":"2014","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib102","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jdermsci.2014.06.001","article-title":"Serum thymus and activation-regulated chemokine (TARC) and interleukin-31 levels as biomarkers for monitoring in adult atopic dermatitis","volume":"75","author":"Kyoya","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2021.01.013_bib103","first-page":"9","article-title":"Serum thymus and activation regulated chemokine (TARC), IL-18 and IL-18 gene polymorphism as associative factors with atopic dermatitis","volume":"24","author":"Gohar","year":"2017","journal-title":"Egypt J Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib104","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/ijd.12992","article-title":"Medium-dose ultraviolet A1 phototherapy and mRNA expression of TSLP, TARC, IL-5, and IL-13 in acute skin lesions in atopic dermatitis","volume":"55","author":"Bogaczewicz","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2249.2005.02875.x","article-title":"Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells","volume":"141","author":"Kagami","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib106","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2011.12.989","article-title":"Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency","volume":"129","author":"Kezic","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib107","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jaci.2017.06.046","article-title":"EASI p-EASI: utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients","volume":"140","author":"Thijs","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib108","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2020.04.138","article-title":"Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation","volume":"84","author":"Glickman","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib109","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.0905-6157.2003.00106.x","article-title":"Does the severity of atopic dermatitis correlate with serum IgE levels?","volume":"15","author":"Laske","year":"2004","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4103\/0019-5154.91827","article-title":"Study of the role of serum folic acid in atopic dermatitis: a correlation with serum IgE and disease severity","volume":"56","author":"Shaheen","year":"2011","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib111","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2133.2000.03667.x","article-title":"Treatment of atopic eczema with oral mycophenolate mofetil","volume":"143","author":"Neuber","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib112","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13601-016-0132-9","article-title":"Immunoglobulin free light chains in adult atopic dermatitis patients do not correlate with disease severity","volume":"6","author":"Thijs","year":"2016","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2021.01.013_bib113","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/imt.15.69","article-title":"Drug evaluation review: dupilumab in atopic dermatitis","volume":"7","author":"Hamilton","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaci.2021.01.013_bib114","first-page":"990","article-title":"Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course\u2014a randomized, placebo-controlled and double blind pilot study","volume":"8","author":"Heil","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaci.2021.01.013_bib115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ijd.13353","article-title":"Omalizumab for atopic dermatitis: case series and a systematic review of the literature","volume":"56","author":"Holm","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib116","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.7754\/Clin.Lab.2017.161107","article-title":"The relationship between serum TARC, TSLP\u00a0and POSTN levels and childhood atopic dermatitis","volume":"63","author":"Uysal","year":"2017","journal-title":"Clin Lab"},{"key":"10.1016\/j.jaci.2021.01.013_bib117","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/pai.12744","article-title":"An association of periostin levels with the severity and chronicity of atopic dermatitis in children","volume":"28","author":"Sung","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib118","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","article-title":"Correlation of IL-31 serum levels with severity of atopic dermatitis","volume":"122","author":"Raap","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib119","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.aller.2017.10.005","article-title":"Assessment of IL-31 levels and disease severity in children with atopic dermatitis","volume":"46","author":"Ozceker","year":"2018","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2021.01.013_bib120","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis","volume":"118","author":"Neis","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib121","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/jdv.13679","article-title":"TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis","volume":"30","author":"Nygaard","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2021.01.013_bib122","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2222.2010.03634.x","article-title":"Elevated umbilical cord serum TARC\/CCL17 levels predict the development of atopic dermatitis in infancy","volume":"41","author":"Miyahara","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2021.01.013_bib123","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1399-3038.2011.01177.x","article-title":"Prediction of atopic dermatitis in 2-yr-old children by cord blood IgE, genetic polymorphisms in cytokine genes, and maternal mentality during pregnancy","volume":"22","author":"Wen","year":"2011","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib124","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.anai.2020.01.022","article-title":"In\u00a0vivo Raman spectroscopy discriminates between FLG loss-of-function carriers\u00a0vs wild-type in day 1-4 neonates","volume":"124","author":"Ni Chaoimh","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib125","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2014.12.013","article-title":"Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year","volume":"135","author":"Kelleher","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib126","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.alit.2015.09.004","article-title":"Transepidermal water loss measurement during infancy can predict the subsequent development of atopic dermatitis regardless of filaggrin mutations","volume":"65","author":"Horimukai","year":"2016","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2021.01.013_bib127","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.jaci.2016.10.026","article-title":"Mathematical modeling of atopic dermatitis reveals \u201cdouble-switch\u201d mechanisms underlying 4 common disease phenotypes","volume":"139","author":"Dominguez-Huttinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192443","article-title":"Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis","volume":"13","author":"Glatz","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2021.01.013_bib129","doi-asserted-by":"crossref","unstructured":"Lauffer F, Baghin V, Standl M, Stark SP, Jargosch M, Wehrle J, et\u00a0al. Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins [published online ahead of print August 13, 2020]. Allergy. https:\/\/doi.org\/10.1111\/all.14557.","DOI":"10.1111\/all.14557"},{"key":"10.1016\/j.jaci.2021.01.013_bib130","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.01.013_bib131","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.01.013_bib132","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.01.013_bib133","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL22 expression in atopic dermatitis patients stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib134","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"26","author":"Khattri","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib135","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2021.01.013_bib136","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.iac.2018.06.004","article-title":"Periostin and dipeptidyl peptidase-4: potential biomarkers of interleukin 13 pathway activation in asthma and allergy","volume":"38","author":"Emson","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2021.01.013_bib137","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1016\/j.jaip.2020.07.015","article-title":"Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures","volume":"8","author":"Glickman","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.01.013_bib138","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jdv.16164","article-title":"Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients","volume":"34","author":"Roekevisch","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2021.01.013_bib139","doi-asserted-by":"crossref","first-page":"21514","DOI":"10.1074\/jbc.271.35.21514","article-title":"Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector","volume":"271","author":"Imai","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2021.01.013_bib140","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1111\/all.13457","article-title":"Incidence of pediatric atopic dermatitis following thymectomy: a Danish register study","volume":"73","author":"Thyssen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.01.013_bib141","first-page":"240","article-title":"Thymus is enlarged in children with current atopic dermatitis. A\u00a0cross-sectional study","volume":"85","author":"Olesen","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2021.01.013_bib142","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1046\/j.1523-1747.2000.00115.x","article-title":"A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin","volume":"115","author":"Vestergaard","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib143","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups\u2014variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib144","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1346-8138.2003.tb00329.x","article-title":"Demonstration of TARC and CCR4 mRNA expression and distribution using in situ RT-PCR in the lesional skin of atopic dermatitis","volume":"30","author":"Zheng","year":"2003","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib146","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-319-64804-0_12","article-title":"Adherence in atopic dermatitis","volume":"1027","author":"Patel","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jaci.2021.01.013_bib147","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jdermsci.2006.06.002","article-title":"Thymus and activation regulated chemokine (TARC)\/CCL17 and skin diseases","volume":"43","author":"Saeki","year":"2006","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2021.01.013_bib148","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/ijd.12281","article-title":"Eosinophilic pustular folliculitis with extensive distribution: correlation of serum TARC levels and peripheral blood eosinophil numbers","volume":"54","author":"Murayama","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib149","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2340\/00015555-1623","article-title":"Elevated serum levels of TARC\/CCL17, eotaxin-3\/CCL26 and VEGF in a patient with Kimura\u2019s disease and prurigo-like eruption","volume":"94","author":"Motegi","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2021.01.013_bib150","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cam4.585","article-title":"CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma","volume":"5","author":"Cuccaro","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.jaci.2021.01.013_bib151","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1002\/art.27678","article-title":"CCL17\/thymus and activation-related chemokine in Churg-Strauss syndrome","volume":"62","author":"Dallos","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2021.01.013_bib152","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaci.2018.06.016","article-title":"Atopic dermatitis in Chinese patients shows TH2\/TH17 skewing with psoriasiform features","volume":"142","author":"Chan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib153","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaci.2007.12.1161","article-title":"Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity","volume":"121","author":"Gupta","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib154","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav2685","article-title":"The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype","volume":"11","author":"Leung","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2021.01.013_bib155","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMra1011040","article-title":"Filaggrin mutations associated with skin and allergic diseases","volume":"365","author":"Irvine","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.01.013_bib156","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4168\/aair.2019.11.1.4","article-title":"Mechanisms by which atopic dermatitis predisposes to food allergy and the atopic march","volume":"11","author":"Tham","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2021.01.013_bib157","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jid.2018.03.1517","article-title":"Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype","volume":"138","author":"Simpson","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib158","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib159","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jaci.2017.10.046","article-title":"Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2-high atopic dermatitis disease endotype","volume":"141","author":"Dyjack","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib160","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bjd.16994","article-title":"A minimally invasive tool to study immune response and skin barrier in children with atopic dermatitis","volume":"180","author":"Hulshof","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib161","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/jdv.14801","article-title":"Concentration of filaggrin monomers, its metabolites and corneocyte surface texture in individuals with a history of atopic dermatitis and controls","volume":"32","author":"Engebretsen","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2021.01.013_bib162","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/s41598-018-20204-8","article-title":"Measurements of AMPs in stratum corneum of atopic dermatitis and healthy skin-tape stripping technique","volume":"8","author":"Clausen","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2021.01.013_bib163","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98006","article-title":"Lipid abnormalities in atopic skin are driven by type 2 cytokines","volume":"3","author":"Berdyshev","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2021.01.013_bib164","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jid.2019.03.1160","article-title":"Side-by-side comparison of skin biopsies and skin tape stripping highlights abnormal stratum corneum in atopic dermatitis","volume":"139","author":"Kim","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.01.013_bib165","doi-asserted-by":"crossref","first-page":"9.23.1","DOI":"10.1002\/cpph.19","article-title":"Biomarkers\u2014a general review","volume":"76","author":"Aronson","year":"2017","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1016\/j.jaci.2021.01.013_bib166","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/all.13223","article-title":"Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues","volume":"72","author":"Brunner","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.01.013_bib167","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaci.2015.03.032","article-title":"Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.01.013_bib169","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1358\/dnp.2002.15.1.660501","article-title":"The role of TARC in the pathogenesis of allergic asthma","volume":"15","author":"Berin","year":"2002","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.jaci.2021.01.013_bib170","first-page":"172","article-title":"Changes in thymus- and activation-regulated chemokine (TARC) associated with allergen immunotherapy in patients with perennial allergic rhinitis","volume":"15","author":"Takeuchi","year":"2005","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:32:13Z","timestamp":1758792733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674921000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":170,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0091674921000968"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.01.013","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers in atopic dermatitis\u2014a review on behalf of the International Eczema Council","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}